Flag of the European Union EU Clinical Trials Register Help

Clinical trials for External beam radiotherapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    73 result(s) found for: External beam radiotherapy. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2012-000967-25 Sponsor Protocol Number: ThoRaT Start Date*: 2012-08-24
    Sponsor Name:
    Full Title: Concomitant Radiotherapy and Erlotinib in advanced lung cancer ThoRaT-studien Thoracal Radiotherapy and Tarceva® An open randomized multicenter phase II study
    Medical condition: Non-small cell lung cancer, - palliative treatment
    Disease:
    Population Age: Adults, Elderly Gender:
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006312-38 Sponsor Protocol Number: SAKK 41/08 Start Date*: 2009-08-05
    Sponsor Name:SAKK (Swiss Group for Clinical Cancer Research)
    Full Title: Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced, K-ras mutated rectal cancer. A randomized multicenter phase I/II trial.
    Medical condition: Advanced K-ras mutated rectal cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000273-39 Sponsor Protocol Number: Start Date*: 2015-07-13
    Sponsor Name:Belfast Health and Social Care Trust
    Full Title: Neo-adjuvant Androgen Deprivation Therapy, Pelvic Radiotherapy and RADium-223 for new presentation T1-4 N0/1 M1B adenocarcinoma of prostate (ADRRAD Trial)
    Medical condition: Metastatic castration sensitive prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-006012-38 Sponsor Protocol Number: SAKK 41/07 Start Date*: 2009-08-04
    Sponsor Name:SAKK (Swiss Group for Clinical Cancer Research)
    Full Title: Neoadjuvant radiotherapy and capecitabine with or without panitumumab in patients with advanced, K-ras unmutated rectal cancer. A randomized multicenter phase II trial.
    Medical condition: Advanced K-ras unmutated rectal cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011325-14 Sponsor Protocol Number: 09-001 Start Date*: 2009-08-11
    Sponsor Name:Cliniques Universitaires Saint-Luc
    Full Title: Phase II Study of Preoperative Panitumumab and External Beam Radiotherapy in Patients with Locally Advanced Rectal Cancer
    Medical condition: Locally advanced adenocarcinoma of the rectum (T3 - T4 and/or N+ M0), previously untreated and non metastatic disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038038 Rectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002340-42 Sponsor Protocol Number: SBG-2-03 Start Date*: 2008-09-16
    Sponsor Name:Biotec Pharmacon ASA
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group phase III clinical study to assess the efficacy and safety of soluble beta 1,3/1,6 glucan (SBG) on oral mucositis in head and neck can...
    Medical condition: Oral mucositis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001917-35 Sponsor Protocol Number: NOX66-005 Start Date*: 2021-10-25
    Sponsor Name:Noxopharm Limited
    Full Title: A Phase 1b/2a Multicenter Study of NOX66 and External Beam Radiotherapy in Patients with Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
    Medical condition: Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-000528-17 Sponsor Protocol Number: IAEA-HypoX Start Date*: 2012-06-05
    Sponsor Name:Department of Experimental Clinical Oncology
    Full Title: A randomized multicenter study of accelerated fractionated radiotherapy with or without the hypoxic radiosensitizer nimorazole in the treatment of squamous cell carcinoma of the head and neck
    Medical condition: Squamous Cell Carcinoma of the Head and Neck region
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SI (Completed) EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001742-13 Sponsor Protocol Number: 06_RADIO_56 Start Date*: 2006-10-04
    Sponsor Name:Christie Hospital NHS Trust
    Full Title: Locally Advanced Pancreatic Cancer: Phase II study of cetuximab and 3-D conformal image-guided radiotherapy (PACER Study)
    Medical condition: Adenocarcinoma of the pancreas which is locally advanced/inoperable
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002258-10 Sponsor Protocol Number: IBRB-02 Start Date*: 2016-10-19
    Sponsor Name:Dermal Laboratories Ltd
    Full Title: SINCERE: A single-centre, assessor blind, randomised pilot study to evaluate the safety, tolerability and acceptability of RB Lotion compared to standard-of-care for Radiation Induced Skin Reaction...
    Medical condition: Radiation Induced Skin Reactions (RISR)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10061103 Dermatitis radiation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005565-54 Sponsor Protocol Number: SBG-2-04 Start Date*: 2008-12-08
    Sponsor Name:Biotec Pharmacon ASA
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group phase III clinical study to assess the efficacy and safety of soluble beta 1,3/1,6 glucan (SBG) on oral mucositis in head and neck can...
    Medical condition: Oral mucositis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007072-42 Sponsor Protocol Number: 20599 Start Date*: 2008-07-08
    Sponsor Name:University Medical Center Utrecht
    Full Title: Double-blind placebo-controlled randomized study to determine the effectiveness of magnesium oxide to reduce the prostate motion.
    Medical condition: Prostate cancer patients who are being treated with external beam radiotherapy using fiducial marker-based position verification.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003873-41 Sponsor Protocol Number: 14-23-16/07 Start Date*: 2015-07-09
    Sponsor Name:MAASTRO Clinic
    Full Title: Non invasive imaging of tumor hypoxia with [18F]HX4 Positron-Emission-Tomography (PET): A phase II trial
    Medical condition: Eligible patients with histologically/cytologically proven primary tumors of the prostate, esophagus, brain or rectum or metastatic disease to the brain (originating from breast, lung or colorectal...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001533-34 Sponsor Protocol Number: 36/2007/O/Sper Start Date*: 2007-04-17
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: A Phase II Study of Panitumumab 5-Fluorouracil and Oxaliplatin in combination with pelvic radiotherapy as treatment of resectable and locally advanced rectal cancer (StarPan Study ﾖ STAR 02)
    Medical condition: rectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10062099 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002200-13 Sponsor Protocol Number: CBGJ398X2201 Start Date*: 2014-05-09
    Sponsor Name:NOVARTIS FARMA S.p.A
    Full Title: A Phase 2, multicenter, open-label study of BGJ398 in patients with recurrent resectable or unresectable Glioblastoma
    Medical condition: recurrent resectable or unresectable Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005877-31 Sponsor Protocol Number: ZK219477-01 Start Date*: 2006-03-27
    Sponsor Name:ISTITUTO NEUROLOGICO CARLO BESTA
    Full Title: Phase II study Systemic treatment with ZK219477 EPOTHILONE in recurrent Glioblastoma patients
    Medical condition: Recurrent Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10018336 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001550-98 Sponsor Protocol Number: C-GBM(XRP6258) Start Date*: 2013-10-04
    Sponsor Name:University Hospital of Ulm
    Full Title: Prospective controlled phase 2 trial of cabazitaxel in patients with temozolomide refractory glioblastoma multiforme (GBM) - The C-GBM Study -
    Medical condition: •Patients with diagnosis glioblastoma multiforme (GBM) WHO grade IV ; •Progression during or within 6 months after last temozolomide treatment; •Time since last temozolomide > 21 days
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005268-71 Sponsor Protocol Number: ML42600 Start Date*: 2021-03-04
    Sponsor Name:Roche Farma S.A.
    Full Title: A PHASE IIIB, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB TO INVESTIGATE SAFETY AND EFFICACY IN SPANISH PATIENTS WITH UNRESECTABLE OR UNSUITABLE FOR LOCOREGIONAL ...
    Medical condition: Treatment for patients with unresectable HCC who have received no prior systemic treatment and are considered unsuitable for locoregional therapy.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-007028-25 Sponsor Protocol Number: ON/2008/2781 Start Date*: 2010-08-17
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: A Randomised Controlled Trial to Determine the Effect of Decapeptyl on Reduction of Prostate Volume Pre-Radiotherapy Compared with Standard Therapy (Zoladex)
    Medical condition: Enrolled patients will be those with a diagnosis of prostate cancer who require radiotherapy to the prostate, with medical castration by means of Luteneising Hormone Releasing Hormone analogue (LRH...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-003736-77 Sponsor Protocol Number: E7080-A001-216 Start Date*: 2023-03-28
    Sponsor Name:Eisai Inc.
    Full Title: A Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
    Medical condition: Recurrent and Refractory Solid Tumors
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 16:21:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA